A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : cHL / classical Hodgkin lymphoma

[Related PubMed/MEDLINE]
Total Number of Papers: 700
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   cHL  (>> Co-occurring Abbreviation)
Long Form:   classical Hodgkin lymphoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients. CI, iPET, LMR
2020 A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. BV, PFS
2020 Adolescents and young adults with classical Hodgkin lymphoma in North Tunisia: Insights from an adult single-institutional study. AYA, EFS, OS, RT
2020 Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. CAR, HL, R/R
2020 Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment. allo-SCT, CR, HID, MRD, NRM, PFS, PR, R/R, RR, S/PD, URD
2020 Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. ASCT, BV, CI, R/R
2020 Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. Bv, RR
2020 Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. PET, PET2, PFS
2020 Checkpoint inhibition therapy as possible frontline therapy for Hodgkin lymphoma. ADCs, HRS
10  2020 Chronic Lymphocytic Leukemia with Divergent Richter's Transformation into a Clonally Related Classical Hodgkin's and Plasmablastic Lymphoma: A Case Report. CLL, PBL
11  2020 Classic Hodgkin lymphoma and Castleman disease: an entity appears to be emerging. CD, HHV-8, HRS, IL-6, WHO
12  2020 Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk-adapted approach in a tertiary cancer center in India. AHL, CR, EFS, ERA, HR, IFRT, IR, LR, LRA, OS
13  2020 Comment on "Fibroblasts in Nodular SclerosingClassical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury" Cancers 2019, 11, 1687. HRS, NS, TIMP3
14  2020 Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. PMBCL
15  2020 Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. HRS
16  2020 CTLA4 haploinsufficiency as a predisposition to classical Hodgkin lymphoma. CTLA-4, EBV, HI
17  2020 Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma. COX-2, RS
18  2020 Diagnosis of classic Hodgkin lymphoma on bone marrow biopsy. EAHP, SH
19  2020 Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. CR, N-AVD
20  2020 Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015. HL, LD, LR, MC, NLPHL, NS
21  2020 Expression of CD47 antigen in Reed-Sternberg cells as a new potential biomarker for classical Hodgkin lymphoma. HRS
22  2020 Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. ASCT, BEGEV, CR, ITT, OS, PFS, R/R
23  2020 Hepatitis B virus infection status is not associated with poor prognosis in classical Hodgkin lymphoma patients. HBsAg, HBV
24  2020 Histology of pediatric classic Hodgkin lymphoma: From diagnosis to prognostic stratification. NS, TCA
25  2020 Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type. LPDs, MTX, PD-L1
26  2020 Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. Bcl, OS, PTCL
27  2020 Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. iTARC, mPFS, PPV, TARC
28  2020 Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. BV, CI, CR, OS, PFS, PR
29  2020 Lymphoma Mimicking Chronic Active Epstein-Barr Virus: A Case Report. CAEBV, EBV, IM
30  2020 Management of children and adolescents with gray zone lymphoma: A case series. GZL, LBCL
31  2020 Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient. RA
32  2020 No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. CMT
33  2020 PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. HRS, TAMs
34  2020 Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? DS, ST
35  2020 Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. allo-HSCT, OS, PFS
36  2020 Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma. EBV
37  2020 Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. IDO1, PD-L1, TAM
38  2020 Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. R/R
39  2020 Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21. miRs, NK
40  2020 Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma. BV, EVs, HRS
41  2020 Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. AID, BV, MTX, RA
42  2020 Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry. EBV, HRS, nPD-L1, SV-CHL
43  2020 Targeted genotyping of circulating tumor DNA for classical Hodgkin Lymphoma monitoring: a prospective study. ctDNA, NGS, PET
44  2020 Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry. CMT, CT
45  2020 The prognostic significance of DeltaSUVmax assessed by PET/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin's lymphoma. DS, PFS
46  2020 The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. FCM, IHC, TAM
47  2020 The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma. EBV, IPS
48  2020 Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. AEs, CR, R/R
49  2020 Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. ASCT, BV, PTCL
50  2020 Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. allo-HCT, auto-HCT, CI, HR, PR-OS
51  2020 Unraveling the Architecture of Classic Hodgkin Lymphoma One Cell at a Time. ---
52  2020 Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma. ABVD, FFP
53  2020 [Classic Hodgkin lymphoma developing early after treatment of follicular lymphoma]. FL, HDT-ASCT, LDH
54  2020 [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses]. auto-HSCT, CR, DLBCL-NOS, IFRT, MGZL, OS, PD, PMBCL, PR, SD
55  2020 [Extranodal manifestation of classical Hodgkin lymphoma in the head and neck region]. ---
56  2020 [Microenvironment in classical Hodgkin lymphoma]. EBV, HRS
57  2020 [Special histopathological variants and potential diagnostic traps of classical follicular dendritic cell sarcoma]. ALCL, EBER, FDCS
58  2019 3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma). AD, LAD, MCcHL, NScCHL
59  2019 A fulminant case of classical Hodgkin lymphoma: A diagnostic dilemma of Epstein-Barr virus-positive large B-cell neoplasms. DLBCL, EBV, HRS
60  2019 A Rare Case of Grey Zone Lymphoma Successfully Treated with Brentuximab Vedotin and R-CHP Chemotherapy. BV, CR, DLBCL, GZL, NHL
61  2019 A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. AE, IRC
62  2019 Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma. CR, PD-1
63  2019 Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients. HGBCL, MDSCs
64  2019 An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. EBV
65  2019 Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement. av, DLBCL, GZL, HRS
66  2019 Autocrine LTA signaling drives NF-kappaB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. HRS, LTA
67  2019 Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. B-NHL, LDH, OS, T-NHL
68  2019 Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. FDG-PET, HSCT, PFS, R/R
69  2019 Changes in EBV Association Pattern in Pediatric Classic Hodgkin Lymphoma From a Single Institution in Argentina. EBV, NS
70  2019 Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma. mDC1, pDC
71  2019 Classic Hodgkin lymphoma with initial extranodal osseous presentation: a case report and literature review. ALCL
72  2019 Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. HRS
73  2019 Classical Hodgkin Lymphoma With Aberrant CD8 Expression: A Clinicopathologic Study of Five Cases. HRS
74  2019 Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin's lymphoma involving extranodal sites: a retrospective single-center. FFP, LDH, LNR, OS
75  2019 Clinical features and treatment outcomes of Hodgkin lymphoma: A retrospective review in a Malaysian tertiary hospital. IQR, OS, PFS
76  2019 Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. IHC, PMLBCL
77  2019 Controversies in the Approach to Initial Therapy of Hodgkin Lymphoma. ---
78  2019 Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. BV
79  2019 Current treatment paradigms for advanced stage Hodgkin lymphoma. ---
80  2019 Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall. AITL, EBV, HRS
81  2019 Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. MCL
82  2019 Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. DNMT, HDACIs, PD-L1, CD274
83  2019 Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma. EBV
84  2019 Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma. HRS, TFs
85  2019 Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury. HRS, MYOCD, NS cHL
86  2019 Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy. ABVD, BMU, PFS
87  2019 Follicular dendritic cells display microvesicle-associated LMP1 in reactive germinal centers of EBV+ classic Hodgkin lymphoma. EBER, EBV, FDCs, GC, LMP1, MC, NS
88  2019 Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. HRS
89  2019 GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities. DLBCLs, EBV, NLPHL, NS, PMBLs, TCHRBCLs
90  2019 Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. CCGs, HRS, MSI, NF-kappaB
91  2019 Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. APOBEC, NF-kappaB, PMBLs
92  2019 Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma. LTR
93  2019 Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA. GZL, LBCL, LYSA
94  2019 High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. TMA
95  2019 Hodgkin lymphoma at Groote Schuur Hospital, South Africa: the effect of HIV and bone marrow infiltration. BMB, BMI, GSH, HIV, HIV-VL, HL, NHLS, NSCHL, OS, SA, TB
96  2019 Hodgkin lymphoma detection and survival: findings from the Haematological Malignancy Research Network. CI, HES
97  2019 Hypoxia-related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapyin classical Hodgkin's lymphoma. HRS, OS, PFS
98  2019 Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment. TAMs
99  2019 Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. ---
100  2019 Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives. ICI, mAb, NHL, R/R